Icahn School of Medicine AT Mount Sinai — Federal Contractor Profile
Mount Sinai's Icahn School of Medicine Secures Over $215 Million in Federal Research Contracts
Contractor Overview
Total Contract Value: $2,903,336,393 ($2.9B)
Total Awards: 27
Company Profile
The Icahn School of Medicine at Mount Sinai, a prominent academic medical institution, engages with the federal government primarily through research and development contracts, leveraging its extensive expertise in biomedical sciences and healthcare. While not a traditional government contractor focused on services or supplies, its role involves advancing medical knowledge and developing innovative solutions that align with national health priorities. The scale of its government business, represented by two contracts totaling over $215 million, indicates a focus on large, complex research initiatives rather than a broad portfolio of smaller engagements. The limited number of contracts suggests a strategic approach, likely targeting specific grant opportunities or research programs where its specialized capabilities are uniquely suited. Information on how these contracts were awarded (competitive vs. sole-source) is not readily available from the provided data, making it difficult to assess their procurement strategy. However, the substantial value of these contracts points to significant contributions in areas such as disease research, public health initiatives, or the development of medical technologies. The concentration of its government business into a few high-value awards suggests a strategy centered on securing major research funding, likely through highly competitive grant processes or direct solicitations for specialized expertise. This approach allows the institution to focus its resources on impactful, long-term research projects that benefit both the scientific community and the public.
Specializations
- Biomedical Research
- Medical Technology Development
- Public Health Initiatives
- Disease Research
- Clinical Trials
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: N/A
Agency Concentration: N/A
Growth Trajectory: stable
Competitive Position
As an academic medical center, Icahn School of Medicine at Mount Sinai operates in a distinct segment of the government contracting landscape, focusing on research and development. Its competitive position is defined by its scientific reputation and specialized research capabilities rather than by traditional service provision. It competes for research grants and contracts against other leading academic institutions and research organizations, often securing funding for highly specialized or groundbreaking projects.
Value to Taxpayers
The value provided to taxpayers by Icahn School of Medicine at Mount Sinai through its government contracts is primarily in the advancement of medical knowledge and the development of potential solutions to pressing health issues. The substantial contract values suggest significant investments in research that could lead to improved public health outcomes, new treatments, or innovative medical technologies. Without more detailed information on the specific outcomes of these contracts, a definitive assessment of value is challenging, but the focus on research indicates a long-term investment in scientific progress.
Agency Relationships
The provided data does not specify the agencies that awarded these contracts, making it impossible to detail which agencies rely on Icahn School of Medicine at Mount Sinai or to assess dependency risks. Typically, academic medical institutions receive funding from agencies like the National Institutes of Health (NIH), the Department of Defense (DoD), or the Department of Veterans Affairs (VA) for research purposes.
Red Flags
- Lack of transparency regarding contract award types (competitive vs. sole-source) prevents a full understanding of procurement practices.
Green Flags
- Focus on high-value research contracts indicates significant scientific expertise and potential for impactful discoveries.
- Substantial contract values suggest the institution is capable of managing large-scale, complex research projects.
Key Contracts
The Icahn School of Medicine at Mount Sinai has been awarded two federal contracts totaling over $215 million. While specific details on these contracts, including the awarding agencies and their precise objectives, are not provided in the summary data, their substantial value suggests they are significant research and development initiatives. These large-scale awards typically indicate a deep level of trust and recognition of the institution's specialized expertise in critical areas of medical science. Such contracts often fund long-term, complex research projects aimed at understanding diseases, developing new therapies, or advancing medical technologies. The ability to secure such significant funding underscores Mount Sinai's standing as a leading research institution capable of undertaking projects with potentially broad public health implications. The nature of these contracts likely involves rigorous scientific inquiry, data analysis, and the dissemination of findings, contributing to the nation's scientific knowledge base and potentially leading to breakthroughs in healthcare.
Frequently Asked Questions
What does Icahn School of Medicine at Mount Sinai do for the government?
The Icahn School of Medicine at Mount Sinai primarily engages with the federal government through research and development contracts. These contracts leverage its extensive expertise in biomedical sciences, healthcare, and medical innovation. The institution undertakes complex research projects, potentially focusing on disease understanding, treatment development, public health initiatives, or the creation of new medical technologies. Its role is to advance scientific knowledge and contribute to national health priorities through rigorous research and discovery.
How much taxpayer money does Icahn School of Medicine at Mount Sinai receive?
Icahn School of Medicine at Mount Sinai has received a total of $215.1 million through two federal government contracts. The average size of these contracts is approximately $107.5 million, indicating that these are substantial, high-value awards. This funding is dedicated to supporting significant research and development activities undertaken by the institution.
Is Icahn School of Medicine at Mount Sinai good value for taxpayer money?
Assessing the value for taxpayer money is challenging without specific contract details and outcomes. However, the substantial investment in research suggests a focus on long-term scientific advancement and potential public health benefits. The institution's role in cutting-edge research implies that taxpayer funds are being directed towards potentially groundbreaking discoveries and innovations that could improve health and well-being.
How does Icahn School of Medicine at Mount Sinai win its contracts?
The provided data does not specify whether Icahn School of Medicine at Mount Sinai wins contracts through competitive bidding or sole-source awards. However, given its nature as an academic medical institution, it is likely that many of its government engagements are secured through competitive grant processes or proposals for specialized research initiatives where its unique expertise is sought.
What agencies use Icahn School of Medicine at Mount Sinai most?
The specific government agencies that have awarded contracts to Icahn School of Medicine at Mount Sinai are not identified in the provided data. Typically, academic medical institutions receive research funding from federal agencies such as the National Institutes of Health (NIH), the Department of Defense (DoD), or other science-focused departments.